X-linked creatine transporter deficiency: clinical aspects and pathophysiology

Area of Science:

• Neuroscience and Genetics
• Biochemistry and Metabolism

Background:

• Creatine transporter deficiency (CTD) is an X-linked disorder identified in 2001, leading to intellectual disability and cerebral creatine deficiency.
• The condition primarily impacts the brain, with muscles being relatively unaffected despite their high creatine requirements.

Purpose of the Study:

• To review current knowledge on creatine metabolism, the creatine transporter (SLC6A8), and the clinical aspects of CTD.
• To explore the mechanisms behind cerebral creatine deficiency, particularly in light of evidence for brain creatine synthesis.
• To discuss the utility of the creatine transporter knockout mouse model for studying CTD.

Main Methods:

• Review of existing literature on creatine metabolism, CTD pathogenesis, and clinical manifestations.
• Analysis of studies investigating creatine synthesis in the brain.
• Evaluation of the creatine transporter knockout mouse model for disease research.

Main Results:

• Creatine transporter deficiency leads to significant intellectual disability due to impaired creatine uptake in the brain.
• Recent findings suggest endogenous creatine synthesis occurs in the brain, posing a paradox for CTD.
• The creatine transporter knockout mouse serves as a valuable model for investigating CTD mechanisms.

Conclusions:

• Understanding the complex mechanisms of cerebral creatine deficiency in CTD is critical.
• Despite exploration of various therapeutic strategies, no effective treatment for CTD has been established.
• Further research into CTD pathogenesis is essential for developing targeted and effective treatments.